Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5426)	9/28/1998 2:38:00 PM
From: Oliver & Co	of 6136

"Lower-Dose Regimen Works for Protease Inhibitor" Reuters (09/25/98) Patients with AIDS may soon be able to take two doses of the protease inhibitor Viracept instead of three, Agouron said Friday. The drug maker said 80 percent of 238 patients taking a higher, twice-daily dosage of Viracept as part of a drug cocktail were able to lower the levels of the virus to a level that was almost undetectable. The response was similar to that achieved by patients taking the drug three times a day in a lower dosage. If the drug is approved, it may erode market share now held by Merck's Crixivan.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next